150 related articles for article (PubMed ID: 36592827)
1. Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study.
Fujii H; Hamano T; Tsuchiya K; Kuragano T; Joki N; Tsuruya K; Honda H; Uemura Y; Nitta K;
Int J Cardiol; 2023 Mar; 375():110-118. PubMed ID: 36592827
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.
Marcelli D; Bayh I; Merello JI; Ponce P; Heaton A; Kircelli F; Chazot C; Di Benedetto A; Marelli C; Ladanyi E; Kroczak M; Stuard S; Grassmann A; Scatizzi L; Brand K; Canaud B
Kidney Int; 2016 Jul; 90(1):192-202. PubMed ID: 27178833
[TBL] [Abstract][Full Text] [Related]
3. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
[TBL] [Abstract][Full Text] [Related]
4. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
[TBL] [Abstract][Full Text] [Related]
5. Relationships among the Dosage of Erythropoiesis-Stimulating Agents, Erythropoietin Resistance Index, and Mortality in Maintenance Hemodialysis Patients.
Pan S; Zhao DL; Li P; Sun XF; Zhou JH; Song KK; Wang Y; Miao LN; Ni ZH; Lin HL; Liu FY; Li Y; He YN; Wang NS; Wang CL; Zhang AH; Chen MH; Yang XP; Deng YY; Shao FM; Fu SX; Fang JA; Cai GY; Chen XM
Blood Purif; 2022; 51(2):171-181. PubMed ID: 34175850
[TBL] [Abstract][Full Text] [Related]
6. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
7. Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis.
Kobayashi S; Tanaka K; Hoshino J; Hara S; Kushiyama A; Tanaka Y; Motonishi S; Sakai K; Ozawa T
Ren Fail; 2022 Dec; 44(1):1801-1810. PubMed ID: 36305202
[TBL] [Abstract][Full Text] [Related]
8. Association between hyporesponsiveness to erythropoiesis-stimulating agents and risk of brain hemorrhage in patients undergoing hemodialysis: the Q-Cohort Study.
Uchida Y; Nakano T; Kitamura H; Taniguchi M; Tsuruya K; Kitazono T
Clin Exp Nephrol; 2023 Jan; 27(1):79-88. PubMed ID: 36100804
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients.
Okazaki M; Komatsu M; Kawaguchi H; Tsuchiya K; Nitta K
Blood Purif; 2014; 37(2):106-12. PubMed ID: 24603656
[TBL] [Abstract][Full Text] [Related]
10. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
[TBL] [Abstract][Full Text] [Related]
11. The influencing factors of the erythropoietin resistance index and its association with all-cause mortality in maintenance hemodialysis patients.
Zhao X; Gan L; Hou FF; Liang X; Chen X; Chen Y; Ni Z; Zuo L
Ren Fail; 2024 Dec; 46(1):2290922. PubMed ID: 38234178
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.
Goodkin DA; Zhao J; Cases A; Nangaku M; Karaboyas A
Am J Nephrol; 2022; 53(5):333-342. PubMed ID: 35462377
[TBL] [Abstract][Full Text] [Related]
13. Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis.
Desai R; Unigwe I; Riaz M; Smith SM; Shukla AM; Mohandas R; Jeon N; Park H
Clin Pharmacol Ther; 2024 Jul; 116(1):217-224. PubMed ID: 38629679
[TBL] [Abstract][Full Text] [Related]
14. Resistance to Erythropoiesis-Stimulating Agents in Pre-Dialysis and Post-Dialysis Mortality in Japanese Incident Hemodialysis Patients.
Hayashi T; Joki N; Tanaka Y; Iwasaki M; Kubo S; Matsukane A; Takahashi Y; Imamura Y; Hirahata K; Hase H
Blood Purif; 2019; 47 Suppl 2(Suppl 1):31-37. PubMed ID: 30943479
[TBL] [Abstract][Full Text] [Related]
15. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.
Rattanasompattikul M; Molnar MZ; Zaritsky JJ; Hatamizadeh P; Jing J; Norris KC; Kovesdy CP; Kalantar-Zadeh K
Nephrol Dial Transplant; 2013 Jul; 28(7):1936-45. PubMed ID: 23045431
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
18. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
[TBL] [Abstract][Full Text] [Related]
19. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study.
Eriguchi R; Taniguchi M; Ninomiya T; Hirakata H; Fujimi S; Tsuruya K; Kitazono T
J Nephrol; 2015 Apr; 28(2):217-25. PubMed ID: 25080399
[TBL] [Abstract][Full Text] [Related]
20. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).
Macdougall IC; Meadowcroft AM; Blackorby A; Cizman B; Cobitz AR; Godoy S; Jha V; Johansen KL; McMahon G; Obrador GT; Wong MG; Singh AK
Am J Nephrol; 2023; 54(1-2):1-13. PubMed ID: 36739866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
